Reprogram Biosciences Closes Seed for Tumor Cell Reprogramming

May 31, 2026

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics for solid tumors, has closed its Seed financing. The company announced the close on May 27, 2026, which brings total capital raised to $6 million since its founding in 2025.

Investors in the round include Unshackled Ventures, 1517 Fund, and Narya. Proceeds will support continued development of the company’s lead program, expansion of its AI discovery engine, and CMC activities.

Reprogram Biosciences is developing a new class of therapeutics based on in situ cell reprogramming. In this approach, mRNA-encoded gene combinations are delivered directly into the tumor, where they activate the immune system by inducing antigen-presenting function in tumor cells.

You may also like

35 Sales Email Tips to Crush Your Sales Game

In today’s digital age, email remains one of the most effective tools for reaching out to potential customers and driving sales. However, crafting a successful sales email can be tricky, as you need […]

Recently Funded Startups Are A Great Sales Target. Here’s Why.

The startup industry has been growing at an unprecedented rate in recent years, with billions of dollars being poured into the sector every year. This growth has created an opportunity for businesses to […]

How to Identify Your B2B Target Audience: A Comprehensive Guide

For any business to succeed, it is essential to target the right audience. In B2B marketing, identifying your target audience is even more important, as it helps you focus your efforts and resources […]